Pharvaris N.V. (PHVS)
PHVS Stock Price Chart
Explore Pharvaris N.V. interactive price chart. Choose custom timeframes to analyze PHVS price movements and trends.
PHVS Company Profile
Discover essential business fundamentals and corporate details for Pharvaris N.V. (PHVS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 2021
Employees
129.00
Website
https://pharvaris.comCEO
Berndt Modig
Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Financial Timeline
Browse a chronological timeline of Pharvaris N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.74.
Earnings released on 12 May 2026
EPS came in at -$0.70 surpassing the estimated -$0.82 by +14.83%.
Earnings released on 2 Apr 2026
EPS came in at -$0.85 falling short of the estimated -$0.71 by -18.34%.
Earnings released on 12 Nov 2025
EPS came in at -$0.70 surpassing the estimated -$0.78 by +10.26%.
Earnings released on 12 Aug 2025
EPS came in at -$0.94 falling short of the estimated -$0.87 by -8.05%.
Earnings released on 13 May 2025
EPS came in at -$0.89 falling short of the estimated -$0.80 by -11.25%.
Earnings released on 31 Mar 2025
EPS came in at -$0.93 .
Earnings released on 13 Nov 2024
EPS came in at -$0.85 falling short of the estimated -$0.66 by -28.79%.
Earnings released on 14 Aug 2024
EPS came in at -$0.59 falling short of the estimated -$0.57 by -3.51%.
Earnings released on 8 May 2024
EPS came in at -$0.56 matching the estimated -$0.56.
Earnings released on 3 Apr 2024
EPS came in at -$0.82 falling short of the estimated -$0.58 by -41.38%.
Earnings released on 2 Nov 2023
EPS came in at -$0.63 surpassing the estimated -$0.67 by +5.97%.
Earnings released on 7 Aug 2023
EPS came in at -$0.69 surpassing the estimated -$0.71 by +2.82%.
Earnings released on 8 May 2023
EPS came in at -$0.72 surpassing the estimated -$0.81 by +11.11%.
Earnings released on 5 Apr 2023
EPS came in at -$0.73 .
Earnings released on 8 Dec 2022
EPS came in at -$0.25 surpassing the estimated -$0.64 by +60.94%.
Earnings released on 1 Jul 2022
EPS came in at -$0.39 .
Earnings released on 11 May 2022
EPS came in at -$0.54 falling short of the estimated -$0.49 by -10.20%.
Earnings released on 29 Mar 2022
EPS came in at -$0.47 surpassing the estimated -$0.74 by +36.49%.
Earnings released on 10 Nov 2021
EPS came in at -$0.46 surpassing the estimated -$0.49 by +6.12%.
Earnings released on 30 Jul 2021
EPS came in at -$1.13 falling short of the estimated -$0.51 by -121.57%.
PHVS Stock Performance
Access detailed PHVS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
